We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+3.22%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$179M
AUM Growth
-$30.2M
Cap. Flow
-$14.6M
Cap. Flow %
-8.15%
Top 10 Hldgs %
63.13%
Holding
65
New
9
Increased
21
Reduced
4
Closed
24

Top Buys

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$7.06M
2
VCYT icon
Veracyte
VCYT
+$6.04M
3
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$4.72M
4
IMMU
Immunomedics Inc
IMMU
+$3.51M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$3.2M

Top Sells

Rank Stock Value
1
OLED icon
Universal Display
OLED
+$10.6M
2
INCY icon
Incyte
INCY
+$4.78M
3
EXEL icon
Exelixis
EXEL
+$3.75M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$3.17M
5
TVTX icon
Travere Therapeutics
TVTX
+$2.58M

Sector Composition

Rank Sector Weight
1 Healthcare 68.86%
2 Technology 2.12%
3 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
$21.1M 11.81%
2,500,000
+997,339
+66% +$7.06M
VCYT icon
2
Veracyte
VCYT
$3.58B
$14.8M 8.26%
2,736,642
+1,020,642
+59% +$6.04M
IMMU
3
DELISTED
Immunomedics Inc
IMMU
$13.8M 7.73%
5,526,172
+1,562,139
+39% +$3.51M
IOVA icon
4
Iovance Biotherapeutics
IOVA
$1.93B
$12.7M 7.1%
2,500,000
+585,000
+31% +$3.2M
NDRM
5
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$11.7M 6.53%
826,799
+349,499
+73% +$4.72M
ASND icon
6
Ascendis Pharma A/S
ASND
$16B
$11.6M 6.47%
623,631
+104,388
+20% +$1.85M
RRM
7
DELISTED
RR MEDIA LTD ORD SHS (ISR)
RRM
$7.95M 4.44%
608,318
+111,091
+22% +$1.13M
CYNA
8
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$7.03M 3.93%
590,530
+213,883
+57% +$2.86M
IRIX icon
9
IRIDEX
IRIX
$14.4M
$6.72M 3.76%
657,670
+200,670
+44% +$1.94M
IWM icon
10
PUT
iShares Russell 2000 ETF
IWM
$81.5B
$5.53M 3.09%
+50,000
New +$5.18M
CPXX
11
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$5.51M 3.08%
+500,000
New +$1.64M
NBRV
12
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$4.88M 2.73%
2,180
+529
+32% +$1.14M
EVDY
13
DELISTED
Everyday Health, Inc.
EVDY
$4.62M 2.58%
824,500
+466,153
+130% +$2.29M
SBBP
14
DELISTED
Strongbridge Biopharma plc.
SBBP
$4.51M 2.52%
1,063,747
+84,840
+9% +$382K
CASM
15
DELISTED
CAS Medical Systems, Inc.
CASM
$3.8M 2.13%
2,678,753
+126,950
+5% +$206K
OLED icon
16
Universal Display
OLED
$3.67B
$3.79M 2.12%
70,000
-217,397
-76% -$10.6M
CEMP
17
DELISTED
Cempra, Inc.
CEMP
$3.68M 2.06%
210,000
-40,000
-16% -$725K
PDSB icon
18
PDS Biotechnology
PDSB
$40M
$3.52M 1.97%
19,255
+11,315
+143% +$2.02M
AKBA icon
19
Akebia Therapeutics
AKBA
$351M
$3.48M 1.95%
+386,308
New +$3.13M
INNL
20
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$3.24M 1.81%
377,765
+57,210
+18% +$477K
OXFD
21
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$3.05M 1.71%
308,044
+117,944
+62% +$1.21M
TVTX icon
22
Travere Therapeutics
TVTX
$5.11B
$2.73M 1.53%
200,000
-170,000
-46% -$2.58M
MRTX
23
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.21M 1.24%
103,283
+14,844
+17% +$332K
ALIM
24
DELISTED
Alimera Sciences
ALIM
$1.71M 0.95%
64,955
– –
RIGL icon
25
Rigel Pharmaceuticals
RIGL
$693M
$1.62M 0.9%
77,684
+32,078
+70% +$791K
1
2 3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q1 2016 Portfolio in Review

As of Q1 2016, Acuta Capital Partners held 65 positions worth $179M, down 14% from $209M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Acuta Capital Partners withdrew a net $14.6M in Q1 2016, closing 24 positions and reducing 4 holdings. Its most notable exit was Incyte, an estimated $4.78M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 66% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Acuta Capital Partners opened a new position in Akebia Therapeutics worth $3.48M.

  • Acuta Capital Partners's largest Q1 2016 buy was Akebia Therapeutics: 386,308 shares worth $3.48M.
  • Acuta Capital Partners added most to Amicus Therapeutics in Q1 2016, an estimated $7.06M increase.
  • Acuta Capital Partners's biggest Q1 2016 reduction was Universal Display, cutting an estimated $10.6M.
  • Acuta Capital Partners fully exited Incyte in Q1 2016, selling an estimated $4.78M.
  • Acuta Capital Partners's ten largest holdings make up 63% of its $179M portfolio in Q1 2016.
  • Acuta Capital Partners opened 9 new positions and closed 24 in Q1 2016.
  • Acuta Capital Partners's portfolio value fell 14% quarter-over-quarter to $179M.

Based on Acuta Capital Partners's 13F filing for Q1 2016, filed 13 May 2016.